Treatment
Cisplatin or Carboplatin clinical trials
We’re tracking 804 recruiting studies that include Cisplatin or Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT03201861RecruitingPhase 3
Cisplatin added after surgery for high-risk breast cancer
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07076212RecruitingPhase 2
Comparing two chemo combos for advanced pancreatic cancer
This study compares two chemotherapy combinations for people with advanced (locally advanced or metastatic) pancreatic cancer that hasn't been treated yet. The goal is to see which combination works better and has fewer side effects.
Charleston, South CarolinaAges 18 years+ - NCT06156514RecruitingPhase 3
Comparing chemo drugs with radiation for advanced cervical cancer
This trial compares two chemotherapy drugs (cisplatin vs. gemcitabine) given together with radiation therapy for locally advanced cervical cancer. The goal is to see which is more effective and has fewer side effects.
Mexico City, Mexico CityAges 18 years+ - NCT07046650RecruitingPhase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07036380RecruitingPhase 2
Testing MP0317 with chemotherapy for advanced bile duct cancer
This trial tests if adding a new drug (MP0317) to standard chemoimmunotherapy helps people with advanced bile duct cancer. It's for patients who haven't had treatment yet, except for certain past adjuvant therapy.
BesançonAges 18 years+ - NCT07043972RecruitingPhase 2
Gemcitabine and carboplatin after EV-pembrolizumab for bladder cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT07017673RecruitingPhase 2
Ivonescimab with chemo for early-stage triple negative breast cancer
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Los Angeles, CaliforniaAges 18 years+ - NCT06998069RecruitingPhase 3
Head and neck cancer study for older adults
This trial tests a combination of chemotherapy and immunotherapy followed by radiation for older adults with head and neck cancer. It aims to see if this approach is safe and effective for people aged 65 and older.
Providence, Rhode IslandAges 65 years+ - NCT06983210RecruitingPhase 2
Combination treatment for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder or urinary tract cancer that has not been treated before. The goal is to see if adding AM80 to standard chemotherapy and immunotherapy works better.
Nagoya, Aichi-kenAges 18–79 - NCT06953323RecruitingPhase 1/Phase 2
Study of WJB001 combination for advanced solid tumors
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06960577RecruitingPhase 2
Perioperative durvalumab with chemotherapy for muscle-invasive bladder cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery can improve outcomes for people with muscle-invasive bladder cancer. It aims to see if this combination is more effective than chemotherapy alone.
ChermsideAges 18 years+ - NCT06923475RecruitingPhase 2/Phase 3
Chemo plus immunotherapy before surgery for bile duct cancer
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
AmsterdamAges 18 years+ - NCT06910072Enrolling by invitationPhase 2/Phase 3
Chemo and immunotherapy before surgery for triple-negative breast cancer
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
BeijingAges 18–75 - NCT06891833RecruitingPhase 2/Phase 3
New drug combo for HER2-positive breast cancer before surgery
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
Bengbu, AnhuiAges 18–75 - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT06830694RecruitingPhase 2
Trial of a new drug combo for a rare type of lung cancer
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Seoul, Gangnam-guAges 19 years+ - NCT06822543RecruitingPhase 2
A new treatment for lung cancer that has spread to the brain
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
Fortaleza, CearáAges 18 years+ - NCT04136535RecruitingPhase 2
Treating resistant lung cancer with chemo plus or minus an added drug
This Phase 2 study tests whether adding an extra targeted medicine (anlotinib) to standard chemotherapy (pemetrexed and carboplatin) can better control osimertinib-resistant lung cancer with an EGFR mutation. It’s for people whose lung cancer has already progressed after osimertinib, and it aims to shrink tumors and slow the disease.
Shenzhen, shenzhenAges 18–75 - NCT06738303RecruitingPhase 2
Cabazitaxel with or without carboplatin vs lutetium PSMA for prostate cancer
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
Cleveland, OhioAges 19 years+ - NCT06095141RecruitingPhase 2/Phase 3
Cisplatin for pancreatic cancer with HRD
This trial tests the drug cisplatin in patients with advanced pancreatic cancer that has a specific DNA repair problem called homologous recombination deficiency (HRD). It may offer a new treatment option for those whose cancer has progressed after at least one prior chemotherapy.
ShanghaiAges 18–80 - NCT06356688RecruitingPhase 2
Study of chemo plus immunotherapy before surgery for esophageal cancer
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Nanjing, JiangsuAges 18–75 - NCT06492460RecruitingPhase 3
Two courses of chemo-radiation after surgery for high-risk head and neck cancer
This trial tests whether giving two rounds of cisplatin chemo along with radiation after surgery can help people with high-risk head and neck squamous cell carcinoma. It is for patients who have already had surgery and whose cancer showed signs of being more aggressive.
Guangzhou, GuangdongAges 18–70 - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+
Common questions
- Are there clinical trials studying Cisplatin or Carboplatin?
- Yes. Clin2 currently lists 804 recruiting studies that include Cisplatin or Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cisplatin or Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cisplatin or Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cisplatin or Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.